| pubmed-article:21623866 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21623866 | lifeskim:mentions | umls-concept:C0079772 | lld:lifeskim |
| pubmed-article:21623866 | lifeskim:mentions | umls-concept:C0221912 | lld:lifeskim |
| pubmed-article:21623866 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:21623866 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:21623866 | pubmed:dateCreated | 2011-7-18 | lld:pubmed |
| pubmed-article:21623866 | pubmed:abstractText | CD20 is a transmembrane protein that is expressed by B cells during their development and is, therefore, commonly used to label cells of B lineage in lymphoid infiltrates. CD20-positive T-cell lymphoma is infrequent but well recognized. Cases reported in the literature show a variety of clinical and histoimmunochemical profiles. Primary cutaneous CD20-positive T-cell lymphoma is vanishingly rare; only eight cases have been previously reported. We present two new cases of this entity and describe their clinical, histological and immunohistochemical features. CD20 is a highly specific B-cell marker. However, it has been reported in a subset of normal T-cells in peripheral blood and bone marrow of healthy individuals. This subset of T-cells also expresses more often CD8 and g/d than the CD20-negative T-cells. Two main theories have been postulated to explain the expression of CD20 by neoplastic T-cells. The first possibility is that these lymphomas develop from the CD20-positive subset of normal T-cells. The second theory regards CD20 as an activation marker. Prognostic implications and therapeutic options of T-cell lymphomas with positivity for CD20 remain to be elucidated. | lld:pubmed |
| pubmed-article:21623866 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21623866 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21623866 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21623866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21623866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21623866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21623866 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21623866 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:21623866 | pubmed:issn | 1600-0560 | lld:pubmed |
| pubmed-article:21623866 | pubmed:author | pubmed-author:WhittakerSean... | lld:pubmed |
| pubmed-article:21623866 | pubmed:author | pubmed-author:RobsonAlistai... | lld:pubmed |
| pubmed-article:21623866 | pubmed:author | pubmed-author:MartinBlancaB | lld:pubmed |
| pubmed-article:21623866 | pubmed:author | pubmed-author:StefanatoCath... | lld:pubmed |
| pubmed-article:21623866 | pubmed:copyrightInfo | Copyright © 2011 John Wiley & Sons A/S. | lld:pubmed |
| pubmed-article:21623866 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21623866 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:21623866 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21623866 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21623866 | pubmed:pagination | 663-9 | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:meshHeading | pubmed-meshheading:21623866... | lld:pubmed |
| pubmed-article:21623866 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21623866 | pubmed:articleTitle | Primary cutaneous CD20-positive T-cell lymphoma. | lld:pubmed |
| pubmed-article:21623866 | pubmed:affiliation | Department of Dermatopathology, St John's Institute of Dermatology, St Thomas Hospital, London, UK. blancamartin@hotmail.com | lld:pubmed |
| pubmed-article:21623866 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21623866 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:21623866 | pubmed:publicationType | Case Reports | lld:pubmed |
